Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2022-11-23 Report Publication Anno…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics - Quarterly report 3Q 2022
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2678 characters) regarding the release of the 3Q 2022 financial results. It does not contain the actual financial statements or substantive financial data, but rather provides a link to where the report can be found. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). 9M 2022
2022-11-23 English
Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022
Report Publication Announcement Classification · 98% confidence The document is a short announcement (3026 characters) stating that Nykode Therapeutics 'will report its financial results for the third quarter of 2022 on November 23, 2022' and will host a webcast presentation. This structure—announcing the future release of results and a related event (webcast)—fits the definition of a Report Publication Announcement (RPA), as it is not the actual financial report itself, but the notice about its upcoming release. It is not an Earnings Release (ER) because it does not contain the actual Q3 2022 financial highlights, only the date they will be announced.
2022-11-16 English
Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer
Earnings Release Classification · 95% confidence The document is titled "Company Announcement" and details the presentation of additional efficacy analysis results from a Phase 2 clinical trial (VB10.16 in cervical cancer). It includes key efficacy data (ORR, DCR) in tabular format and mentions that the data will be presented at the Credit Suisse Annual Healthcare Conference. This format—a press release announcing clinical data updates and referencing an upcoming presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full quarterly/interim report (IR) or a transcript (CT), and it is a direct announcement of results rather than just a notice of publication (RPA), the most fitting category is Earnings Release (ER), as these announcements often contain the core financial/clinical performance highlights for a period or study update. It is not a formal regulatory filing like a 10-K or a specific shareholder document. FY 2022
2022-11-07 English
Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer
Regulatory Filings Classification · 95% confidence The document is an announcement from Nykode Therapeutics detailing 'additional efficacy analysis' results from a Phase 2 clinical trial (VB10.16 in cervical cancer). It presents key efficacy metrics (ORR, DCR) broken down by prior treatment lines and metastasis burden. This content is characteristic of an Earnings Release (ER) or a specific clinical data update that serves as an initial announcement of results, rather than a comprehensive quarterly/annual report (IR/10-K) or a formal presentation deck (IP). Since it focuses on announcing new, specific financial/clinical performance highlights, ER is the most appropriate classification. It is not a transcript (CT), a formal report (AR/IR), or a presentation (IP), but rather a press release summarizing data.
2022-11-07 English
Nykode Therapeutics to present at two upcoming investor conferences in November
Report Publication Announcement Classification · 99% confidence The document is a short company announcement stating that the CEO and CBO will present at two upcoming investor conferences (Credit Suisse Annual Healthcare Conference and Jefferies London Healthcare Conference) in November. It provides the dates and mentions that presentation slides will be accessible on the website. This is not a full report (like 10-K or IR), nor is it a formal regulatory filing detailing a specific event like a dividend or director dealing. It is an announcement about the company's participation in investor events, which aligns best with an Investor Presentation (IP) announcement or, more generally, a Report Publication Announcement (RPA) if the presentation materials themselves are the focus, or simply a general announcement. Given the content is about presenting at investor conferences, the most fitting category is Investor Presentation (IP), as these presentations are the core material being discussed. However, since the document itself is an announcement *about* the presentations and not the presentation slides themselves, and it explicitly mentions where the slides can be accessed, it strongly fits the definition of a Report Publication Announcement (RPA) if we interpret 'report' broadly to include investor materials, or it could be classified as a general Regulatory Filing (RNS) if RPA is reserved for formal report publications. Since the document is short and announces the availability of presentation materials, RPA is a strong candidate, but IP is the subject matter. Given the context of 'presenting' at conferences, which often involves distributing an Investor Presentation, I will lean towards IP as the intended material, but since this is the announcement *of* the presentation schedule, RPA is technically more accurate based on Rule 2. However, IP is a specific category for investor materials. Let's re-evaluate the definitions. IP is 'Investor Presentation'. This document announces *when* they will present. If the slides were attached, it would be IP. Since it announces the event and points to where the slides will be, it is an announcement of future material. I will classify it as an Investor Presentation (IP) because the core subject matter is the presentation itself, even if this is the announcement wrapper, as it is more specific than RPA or RNS.
2022-11-07 English
Nykode Therapeutics to present at two upcoming investor conferences in November
Regulatory Filings Classification · 99% confidence The document is a press release announcing that Nykode Therapeutics executives will be presenting at two upcoming investor conferences (Credit Suisse Annual Healthcare Conference and Jefferies London Healthcare Conference) in November. It provides dates, mentions that presentation slides will be accessible on the company website, and includes general company information. This type of announcement, which details participation in investor events where presentations are given, aligns best with the 'Investor Presentation' (IP) category, as the core purpose is to inform investors about upcoming opportunities to view company material, even if the material itself is not attached here. However, since the document is an *announcement* about presentations and not the presentation slides themselves, and it is a general corporate update, it could also be considered a Regulatory Filing (RNS) or potentially related to Investor Relations (IR). Given the specific mention of presentations and investor conferences, 'Investor Presentation' (IP) is the most descriptive category for the *subject matter*, but following the 'MENU VS MEAL' rule, since this is an announcement *about* presentations rather than the presentation itself, and it's a general corporate update, 'Regulatory Filings' (RNS) serves as a strong fallback for announcements that don't fit the specific report types. Since the content is purely about investor outreach and conference participation, and not a specific financial report (like 10-K, IR, ER), I will classify it as an Investor Presentation (IP) as it directly relates to the dissemination of investor materials, even if it's just the schedule.
2022-11-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.